Pharma Manufacturing World Summit

Eamonn Warren serves as Group Vice President of API and Dry Products Manufacturing at Eli Lilly and Company, where he leads the global network of internal and external manufacturing sites responsible for active pharmaceutical ingredients and dry-product production. He assumed this role in 2024 and is a member of Lilly’s Manufacturing Leadership Team.

Eamonn began his career with Lilly in 1995 at the Kinsale manufacturing site in Ireland as an automation engineer. Over the course of nearly three decades, he has held roles of increasing responsibility across engineering, operations, Six Sigma, human resources, and site leadership. His international experience includes assignments in Puerto Rico, Indianapolis, Augusta in the state of Georgia, and the Fegersheim manufacturing site in France.

Prior to his current position, Eamonn served as the global lead for Lilly’s Parenteral Manufacturing Network, where he oversaw strategy, performance, and modernization across Lilly’s sterile manufacturing capabilities. He is recognized for championing advanced and innovative manufacturing approaches as well as for his focus on operational excellence, talent development, and regulatory rigor.

A native of Ireland, Eamonn holds a degree in Chemical Engineering from University College Dublin and a degree in Management and Marketing from University College Cork.

Dr Mire-Sluis is currently Head of Quality for Gilead Sciences. He was Head of Global Quality for AstraZeneca and Vice President, North America, Singapore, Contract and Product Quality at Amgen Inc. He was previously Principal Advisor, Regulatory Science and Review, Office of Biotechnology Products, CDER and Head of Analytical Sciences and Standards, Office of the Director, CBER, FDA, in Bethesda, Maryland.

He trained in Genetics and Biometry and has a PhD in Cell biology and Biochemistry. Dr Mire-Sluis was the Head of the Cytokine Group in the Division of Immunobiology at the National Institute for Biological Standards and Control, Potters Bar, UK. Dr Mire-Sluis specialized in the development of assays for the characterization and quantitation of biological products. He then became Director of BioAnalytical Sciences at Genentech and prior to joining FDA, was Executive Director of Analytical Sciences at CancerVax Corporation, San Diego.

Dr. Advant has served as Savara’s Executive Vice President, Global Technical Operations since March 2024. With approximately three decades of experience in the biopharmaceutical sector, he has considerable expertise in drug substance, drug product, and analytical development with early- and late-stage clinical and commercially approved biologics. Dr. Advant also has extensive expertise in technology transfer, scale-up and cGMP manufacturing (both internal and external) in a highly regulated environment. To date, Dr. Advant has helped launch multiple biologic assets across several therapeutic areas. Prior to joining Savara, he was VP, Manufacturing Operations at GSK, where he was responsible for multi-site drug substance and drug product operations. Previously he held roles of increasing responsibility at Celgene Corporation (acquired by Bristol Myers Squibb), Kemwell BioPharma, ImClone/Lilly, and Diosynth Biotechnology (now FujiFilm Diosynth Biotechnolgy), among others. Dr. Advant holds a Ph.D. in Pharmaceutics from the University of Connecticut.

Anne Kantardjieff, PhD, is Vice President and Head of CMC Development and Regulatory for Biologics and Advanced Therapies at Biogen. She is a seasoned biopharmaceutical executive with over 15 years of experience advancing complex biologics and cell and gene therapies from early development through global commercialization.

Anne is recognized across the industry for her expertise in CMC strategy, manufacturing scalability, and regulatory integration for advanced modalities. She leads global teams responsible for development, technical transfer, and regulatory CMC strategy across a diverse portfolio of biologics and ATMP programs, partnering closely with R&D, Quality, and Commercial Operations to enable reliable, inspection-ready supply and accelerated patient access.

Prior to Biogen, Anne served as Vice President of Manufacturing and MSAT at bluebird bio, where she led end-to-end supply and technical operations for four commercially approved autologous gene therapies—Zynteglo, Skysona, Abecma, and Lyfgenia. In this role, she oversaw external manufacturing partnerships, process validation, regulatory inspections, and commercial launch execution across multiple global markets.

Earlier in her career at bluebird bio, Anne drove strategic process improvements, expanded manufacturing capacity, and played a pivotal role in successful product approvals. She previously held leadership roles at Alexion Pharmaceuticals, where she led early- and late-stage process development teams and contributed to the commercialization of Strensiq, Kanuma, and Ultomiris.

Anne is known for building high-performing, collaborative organizations and integrating technical rigor with strategic decision-making to modernize manufacturing platforms and enable modality agility.

She holds a PhD in Chemical Engineering from the University of Minnesota and a Bachelor of Engineering in Chemical Engineering from McGill University. She is widely published and has held leadership roles within the American Chemical Society’s Biochemical Technology Division.